Skip to main content

Advertisement

Table 1 Characteristics of the 12 patients

From: A phase 0 study of the pharmacokinetics, biodistribution, and dosimetry of 188Re-liposome in patients with metastatic tumors

No. Sex Age Primary cancer TNM Stage Metastasis Total %IDa %ID/kgb
1 F 48 Breast T2N2M2 IV Bone 0.025 3.00
2 M 48 Esophagus T1N0M1 IV Pelvis 0.001 1.41
Rectum 0.003 1.03
3 M 46 Liver T3N0M1 IV Bone 0.025 2.78
Lung 0.004 3.56
Liver) 2.580 9.03
4 F 61 Kidney T4N0M1 IV Bone 0.068 0.76
Lung 0.001 3.22
7 F 58 Colon T4N1M1 IV Liver 0.017 10.12
8 F 46 Sarcoma T2N0M1 IV Lung 0.064 11.35
Liver 0.018 7.36
9 M 66 Colon T3N2M1 IV Lung 0.083 3.71
10 M 63 Colon T3N2M1 IV Lung 0.012 2.10
11 M 64 Esophagus T3N0M1 IV Lung 0.061 3.99
12 M 80 Colon T3N2M1 IV Abdomen 0.029 1.37
Bladder 0.040 1.10
(Liver) 0.048 13.57
13 F 55 Colon T4N1M1 IIIB Lung 0.002 4.94
14 M 62 NPC T2N1M1 IV Lung 0.052 7.87
  1. aHighest tumor uptake determined from ROI on 24-h SPECT imaging
  2. bPercentage injected activity per kilogram calculated from estimated tumor volume